It should be considered hypothesis generating until dedicated RCTs or patient-level meta-analyses are conducted to prove causality and elucidate the specific mechanism of action of SGLT2 inhibitors in influencing the different pathways leading to AF in different cardiovascular diseases. Here, SLC5A2 is linked to atrial fibrillation.